Search Clinical Trials
Parent Therapeutic Areas: Gastroenterology | Immunology/Infectious Diseases

Hepatitis

California

Anaheim : Advanced Clinical Research Institute

Hepatitis C research study for Latino and non-Latino patients who are treatment Naïve.

Palo Alto : Stanford University School of Medicine

Randomized, Multicenter, Open Label, Phase IV Study Evaluating the Efficacy and Safety of 16-Week Versus 24-Week Treatment with PEGASYS in Combination with Copegus in Interferon-naïve Patients with Chronic Hepatitis C Genotype 2 or 3 Virus Infection

New Jersey

Egg Harbor Township : AGA Clinical Research Associates, LLC

Hepatitis C Infection

New York

Manhasset : Biomedical Research Alliance of New York

Treatment Naïve Subjects with Genotype 1 Chronic Hepatitis C - Adults

New York : Mount Sinai Medical Center

A Prospective, Multicenter, Open-Label, Comparative, Efficacy Study of Pegasys plus Copegus in Treatment-Naive Latino Patients with Chronic Hepatitis C-Genotype 1, as Compared to Treatment-Naive Non-Latino Caucasian Patients with Chronic Hepatitis C-Genotype 1 (ML18179)

New York : Mount Sinai Medical Center

A Randomized, Double-Blind, Controlled Evaluation of Tenofovir DF versus Adefovir Dipivoxil for the Treatment of Presumed Pre-core Mutant Chronic Hepatitis B [GS-US-174-0102]

New York : Biomedical Research Alliance of New York

Chronic Hepatitis C- Non-Responsive to Prior Interferon Alfa Treatment

New York : Mount Sinai Medical Center

Comparison of Peg-Intron 1.5 ug/kg/wk Plus Rebetol vs. Peg-Intron 1 ug/kg/wk Plus Rebetol vs. Pegasys 180 ug/wk Plus Copegus in Previously Untreated Adult Subjects With Chronic Hepatitis C Infected With Genotype 1 [P03471]

Italy

Cagliari : Research Site:

A Study of PEGASYS (Peginterferon alfa-2a (40KD)) With or Without Ribavirin in Patients With Chronic Hepatitis D (CHD)

Romania

Bucharest : Research Site:

A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With Chronic Hepatitis D (CHD)

Cluj-Napoca : Research Site:

A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With Chronic Hepatitis D (CHD)

Constanta : Research Site:

A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With Chronic Hepatitis D (CHD)

Craiova : Research Site:

A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With Chronic Hepatitis D (CHD)

Iasi : Research Site:

A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With Chronic Hepatitis D (CHD)

Timisoara : Research Site:

A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With Chronic Hepatitis D (CHD)